AUGMENT: Lenalidomide plus Rituximab in R/R Follicular Lymphoma

Opinion
Video

Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Related Content
This was the first trial for patients with late-stage WM to show the potential for complete responses with a chemotherapy-free immunotherapy.

Novel CD19 CAR-NK Therapy Yields Responses in Waldenstrom Macroglobulinemia

Tim Cortese
August 22nd 2025
Article
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
August 22nd 2025
Podcast
Pre-planned interim results from the phase 3 EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

SC Epcoritamab Combo Meets ORR/PFS End Points in R/R Follicular Lymphoma

Tim Cortese
August 22nd 2025
Article
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
August 22nd 2025
Podcast
FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL

FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL

Tim Cortese
August 22nd 2025
Article
The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana, LLC.

FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma

Tim Cortese
August 22nd 2025
Article